The endocannabinoid system and the brain.
By R. Mechoulam, L. Parker. Annual Review of Psychology, 2013
1,009 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Pharmacology
View Paper: https://www.semanticscholar.org/paper/5a439a069a4e00814df06a50c9c214cf3d6c8565
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
- P. Castillo
- Marilyn Huestis
- Nathalie A. Desrosiers
- Y. Hashimotodani
- D. Gorelick
- M. Castaneto
- R. Hartman
- Sandrine Pirard
In Pharmacology
- P. Castillo
- Marilyn Huestis
- Nathalie A. Desrosiers
- Y. Hashimotodani
- D. Gorelick
- M. Castaneto
- R. Hartman
- Sandrine Pirard
Citations in the corpus
- Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications (2014, background): “CB1 agonist activation down regulates adenylyl cyclase and decreases cellular cAMP levels, which triggers a cascade of reactions that affects cellular signaling and neurotransmitter inhibition, including acetylcholine, dopamine, noradrenaline, and glutamine, and γ-aminobutyric acid (GABA) (Mechoulam”
- Endocannabinoid signaling and synaptic function (2012, background): “Moreover, dysregulation of the eCB system is implicated in neuropsychiatric conditions such as depression and anxiety (Hillard et al., 2012; Mechoulam and Parker, 2012).”
- Neurobiological Interactions Between Stress and the Endocannabinoid System (2016, background): “The eCB system nomenclature derives from the finding that eCBs and plant-derived cannabinoids converge on a common molecular receptor target (Mechoulam and Parker, 2013).”